
Ligand (LGND) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
167.1M
Gross Profit
156.1M
93.37%
Operating Income
23.0M
13.77%
Net Income
-4.0M
-2.41%
EPS (Diluted)
-$0.22
Balance Sheet Metrics
Total Assets
941.8M
Total Liabilities
111.3M
Shareholders Equity
830.4M
Debt to Equity
0.13
Cash Flow Metrics
Operating Cash Flow
68.7M
Free Cash Flow
77.4M
Revenue & Profitability Trend
Ligand Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 167.1M | 131.3M | 196.2M | 241.5M | 163.6M |
Cost of Goods Sold | 11.1M | 10.5M | 52.8M | 62.2M | 30.4M |
Gross Profit | 156.1M | 120.8M | 143.4M | 179.4M | 133.1M |
Operating Expenses | 100.1M | 77.3M | 106.1M | 41.3M | 101.1M |
Operating Income | 23.0M | 9.8M | 3.0M | 103.9M | 20.4M |
Pre-tax Income | 2.5M | 63.7M | 36.0M | 72.2M | 1.3M |
Income Tax | 6.6M | 9.8M | 41.2M | -4.1M | -5.3M |
Net Income | -4.0M | 52.2M | -33.4M | 57.1M | -3.0M |
EPS (Diluted) | -$0.22 | $2.94 | -$1.98 | $3.34 | -$0.18 |
Income Statement Trend
Ligand Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | 331.6M | 237.4M | 263.6M | 464.8M | 500.6M |
Non-Current Assets | 610.2M | 549.8M | 499.1M | 832.8M | 861.7M |
Total Assets | 941.8M | 787.2M | 762.7M | 1.3B | 1.4B |
Liabilities | |||||
Current Liabilities | 37.1M | 16.8M | 98.8M | 41.7M | 100.1M |
Non-Current Liabilities | 74.2M | 69.5M | 66.4M | 434.8M | 552.6M |
Total Liabilities | 111.3M | 86.3M | 165.2M | 476.4M | 652.8M |
Equity | |||||
Total Shareholders Equity | 830.4M | 700.9M | 597.5M | 821.2M | 709.5M |
Balance Sheet Composition
Ligand Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -4.0M | 52.2M | -33.4M | 57.1M | -3.0M |
Operating Cash Flow | 68.7M | 93.3M | 170.6M | 67.4M | 50.8M |
Investing Activities | |||||
Capital Expenditures | -1.8M | -3.5M | -17.9M | -8.8M | -4.5M |
Investing Cash Flow | -133.3M | 38.2M | 163.5M | 30.0M | 230.3M |
Financing Activities | |||||
Dividends Paid | - | - | - | - | - |
Financing Cash Flow | 31.6M | -82.4M | -279.2M | -171.5M | -313.6M |
Free Cash Flow | 77.4M | -4.3M | 119.9M | 70.0M | 50.1M |
Cash Flow Trend
Ligand Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
46.27
Forward P/E
19.31
Price to Book
2.80
Price to Sales
12.28
PEG Ratio
19.31
Profitability Ratios
Profit Margin
-73.07%
Operating Margin
-80.87%
Return on Equity
-16.56%
Return on Assets
-1.14%
Financial Health
Current Ratio
5.27
Debt to Equity
0.56
Beta
0.71
Per Share Data
EPS (TTM)
-$7.29
Book Value per Share
$41.27
Revenue per Share
$9.73
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
lgnd | 2.2B | 46.27 | 2.80 | -16.56% | -73.07% | 0.56 |
Vertex | 124.2B | 32.82 | 7.53 | -5.64% | -8.91% | 10.00 |
Regeneron | 59.1B | 13.92 | 1.97 | 15.96% | 31.94% | 9.20 |
Blueprint Medicines | 8.3B | -120.14 | 24.23 | -47.71% | -27.70% | 208.50 |
Roivant Sciences | 7.4B | 1.95 | 1.61 | -12.54% | 96.86% | 1.93 |
Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.